Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm Phase II Trial of Circulating Tumor DNA-guided Adjuvant Therapy With Elacestrant in Adults With Hormone Receptor Positive HER2 Negative Breast Cancers at Risk for Late Recurrence (CATE)

NCT06923527 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT06923527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06923527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm Phase II Trial of Circulating Tumor DNA-guided Adjuvant Therapy With Elacestrant in Adults With Hormone Receptor Positive HER2 Negative Breast Cancers at Risk for Late Recurrence (CATE)
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Recruiting
Start date
September 30, 2025
Completion date
September 30, 2027
Enrollment
50 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

er+ breast cancer